A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent, Versus Placebo in the Treatment of Post Herpetic Neuralgia.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs SLC 022 (Primary)
- Indications Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- 31 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Jan 2009 The number of trial centres changed from 3 to 21, as reported by clinicalTrials.gov record.
- 20 Jan 2009 Status changed from not yet recruiting to recruiting, according to a Solace Pharmaceuticals media release.